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Abstract
Background: Areas that are endemic for malaria are also highly endemic for hepatitis B virus (HBV) infection. Nevertheless, it
is unknown whether HBV infection modifies the clinical presentation of malaria. This study aimed to address this question.
Methodology and Findings: An observational study of 636 individuals was performed in Rondo ˆnia, western Amazon, Brazil
between 2006 and 2007. Active and passive case detections identified Plasmodium infection by field microscopy and nested
Polymerase Chain Reaction (PCR). HBV infections were identified by serology and confirmed by real-time PCR.
Epidemiological information and plasma cytokine profiles were studied. The data were analyzed using adjusted
multinomial logistic regression. Plasmodium-infected individuals with active HBV infection were more likely to be
asymptomatic (OR: 120.13, P,0.0001), present with lower levels of parasitemia and demonstrate a decreased inflammatory
cytokine profile. Nevertheless, co-infected individuals presented higher HBV viremia. Plasmodium parasitemia inversely
correlated with plasma HBV DNA levels (r=20.6; P=0.0003).
Conclusion: HBV infection diminishes the intensity of malaria infection in individuals from this endemic area. This effect
seems related to cytokine balance and control of inflammatory responses. These findings add important insights to the
understanding of the factors affecting the clinical outcomes of malaria in endemic regions.
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Introduction
Malaria continues to be a major health threat worldwide. Most
regions highly endemic for malaria are also endemic for other
infectious diseases, which may affect the malaria infection [1]. In this
context, hepatitis B virus (HBV) infections are common in many of
the malaria endemic areas. HBV induces a robust pro-inflammatory
Type 1 immune response (Th1), which is important for Plasmodium
clearance, but is also implicated in disease severity [2]. Whilst
intriguing, little is known of the effects of HBV on the clinical
presentationofmalaria. IntrahepaticHBV replication isinhibited by
P. yoelii infection in mice [3], and there is enhanced interferon (IFN)-
c and IFN-a/b production in the liver. In humans, results from a
small investigation suggest that acute falciparum malaria modulates
HBV viremia in patients with chronic HBV infection [4]. Moreover,
a study performed in a Vietnamese hospital showed that patients
with cerebralmalaria had a slightly greaterriskofregistering positive
serology for the HBV surface antigen (HBSAg) [5]; however, this
study did not show a significant association between the overall risk
of death caused by severe falciparum malaria and positivity for
HBSAg [5]. There is no clear evidence that the clinical status of
underlying hepatitis B-related liver disease is affected during malaria
infection. In addition, the impact of HBV infection on malaria
symptoms has not been adequately addressed. Here, we report a
study aimed at comparing co-infected individuals to individuals with
single infections of HBV or P. falciparum and/or P. vivax to evaluate
how HBV infection influences the malaria burden in a region from
the Brazilian Amazon.
Methods
Ethics statement
Written informed consent was obtained from all participants or
their legally responsible guardians, and all clinical investigations were
conducted according to the principles expressed in the Declaration of
Helsinki. The project was approved by the institutional review board
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19841of the Faculdade de Medicina, Faculdade Sa ˜o Lucas, Rondo ˆnia,
Brazil, where the study was performed.
Study locality
A field observational study was performed between May 2006
and September 2007 in Rondo ˆnia State (10u12’43’’ S; 63u49’44’’
W), Brazilian Amazon. In this region, most malaria cases occur
between April and September, with a high risk of infection [6,7].
Rondo ˆnia accounts for 19% of malaria cases in the Brazilian
Amazon (112,165 symptomatic cases in 2005), with an estimated
prevalence of 8% [8]. P. vivax infection represents up to 80% of the
malaria cases in Brazil, and P. falciparum infection accounts for
Table 1. Baseline characteristics of the subjects.
Current malaria
Variables
Non-infected
n=205
Symptomatic infection
n=210
Asymptomatic infection
n=221
P value
x2
n( % ) n( % ) n( % )
Gender 0.227
Male 88 (42.93) 107 (50.95) 99 (44.80)
Age (years) ,0.0001
5 to 15 14 (6.83) 25 (11.90) 1 (0.45)
16 to 30 50 (24.39) 66 (31.43) 36 (16.29)
31 to 59 98 (47.80) 83 (39.52) 145 (65.61)
$60 21 (10.24) 21 (10.0) 20 (9.05)
Years residing in the area ,0.0001
#2 44 (21.46) 56 (26.67) 34 (15.38)
3 to 10 20 (9.76) 41 (19.52) 19 (8.60)
.10 119 (58.05) 195 (92.86) 149 (67.42)
Residents per household ,0.0001
1 to 5 141 (68.78) 113 (53.81) 147 (66.52)
.5 42 (20.49) 82 (39.05) 55 (24.89)
HBV infection ,0.0001
Non-infected 89 (43.41) 140 (68.30) 97 (43.89)
Previous HBV 65 (31.70) 51 (24.30) 77 (34.84)
Current HBV 29 (14.15) 04 (1.90) 28 (12.67)
Vaccinated 22 (10.73) 15 (7.14) 19 (8.60)
Malaria diagnosis { ,0.0001
Negative 205 (100) - -
P. vivax - 190 (90.48) 173 (78.28)
P. falciparum - 15 (7.14) 41 (18.55)
P. vivax + P. falciparum - 05 (2.38) 07 (3.17)
Malaria episodes ,0.0001
None 24 (11.71) 25 (11.90) 03 (1.36)
1 to 4 07 (3.41) 58 (27.62) 03 (1.36)
5 to 10 29 (14.15) 49 (23.33) 07 (3.17)
.10 123 (60.0) 63 (30.0) 189 (85.52)
Plasma IL-10 (pg/mL) 1 ,0.0001
#46 175 (85.37) 147 (70.0) 51 (23.08)
.46 08 (3.90) 48 (22.86) 151 (68.33)
Plasma IFN-c (pg/mL) 1 ,0.0001
#198 154 (75.12) 116 (55.24) 148 (66.97)
.198 29 (14.15) 79 (37.62) 54 (24.43)
A Chi-square test was performed to compare the distribution of each variable between the groups.
Individuals presenting AgHBS
2/anti-HBS
+/anti-HBc
+ with no HBV DNA amplification by quantitative RT-PCR (qPCR) were considered to have previous HBV infection,
those presenting AgHBS
+/anti-HBS
2 and detectable viremia by qPCR were considered currently infected with HBV and those with AgHBS
2/anti-HBS
+/anti-HBc
2 were
considered vaccinated against the virus.
{Malaria diagnosis was based on light microscopy and confirmed by a nested RT-PCR molecular test, as described in methods.
1Cut-off IL-10 and IFN- c plasma levels were determined by choosing the values that implied the highest likelihood ratio in discriminating asymptomatic from
symptomatic malaria infection using a ROC analysis.
doi:10.1371/journal.pone.0019841.t001
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communities. Although rare, fatal cases P. vivax infection have
been reported in Brazil [10,11]. In contrast, asymptomatic
infections by P. falciparum and P. vivax have been detected in
epidemiological surveys in some regions of the Brazilian Amazon,
indicating that clinical immunity does exist in both autochthonous
and migrant populations [12,13]. The incidence of HBV infection
was 20.4 per 100,000 inhabitants in 2004 with a mortality rate of
7.43 per million, which is more than three times higher than the
national mean of 2.37 [8]. Previous studies in the Brazilian
Amazon have primarily tried to estimate co-infection rates [14].
Study design and sampling
Both active and passive malaria case detection and diagnosis
of HBV infection were performed. These included home visits in
areas of high transmission, and study of individuals seeking care
at the diagnostic centers of Brazilian National Foundation of
Health (FUNASA). Individuals of both sexes, ranging in age
from five to seventy years, who had resided in the endemic area
for more than six months, were invited to participate. Exclusion
criteria were as follows: documented viral hepatitis (A, C, and
D), chronic alcoholism, human immunodeficiency virus type 1
infection, yellow fever, leptospirosis, cancer and chronic
degenerative diseases, sickle cell trait and the use of hepatotoxic
or immunosuppressant drugs. Twelve individuals withdrew
consent and were excluded from the study. The study
participants were interviewed and examined by a physician,
and 20 mL of venous blood and thick blood smears were
collected. Plasma samples and total blood were stored in liquid
nitrogen. Total blood samples were used for molecular diagnosis
Figure 1. Screening and enrollment. The study participants were stratified according to the clinical presentation of Plasmodium sp. infection
(non-infected, asymptomatic and symptomatic malaria). Simultaneously, the presence of HBV infection was verified to identify co-infections.
doi:10.1371/journal.pone.0019841.g001
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facilities in Salvador, Bahia, Brazil.
Malaria diagnosis was performed using microscopic examina-
tion of thick smears, and parasitemia (parasites/mL of blood) was
calculated in positive cases. Nested PCR was performed as
described previously [15], using whole blood samples from all
individuals to confirm diagnoses. After obtaining the parasitolog-
ical diagnosis, all positive cases were followed up for 30 days for
the evaluation of malaria symptoms. Individuals who tested
positive for Plasmodium infection without any presumptive malaria
symptoms were considered asymptomatic, whereas cases with
positive parasitological tests in the presence of symptoms were
classified as symptomatic. Study individuals were then classified
into three groups according to Plasmodium infection: non-infected
(n=205) or Plasmodium-infected (P. vivax and/or P. falciparum) and
either symptomless (n=221) or symptomatic (n=210) (Table 1).
Only two cases of P. malariae infection were detected, and these
were excluded from the study (Figure 1).
Diagnosis of HBV infection was performed at the State Central
Laboratory (LACEN) of Salvador, Bahia, Brazil, using the
AXSYMH automatic ELISA system (Abbott, Wiesbaden, Ger-
many). All individuals were screened for HBSAg, total anti-HBS,
total anti-HBc, anti-HBc IgM, HBeAg and anti-HBe IgG. We
found that 326 individuals presented no markers of HBV exposure
(HBSAg
2/anti-HBS
2/anti-HBc
2), 193 presented markers of
previous HBV infection (HBSAg
2/anti-HBS
+/anti-HBc
+), 61
were currently infected (HBSAg
+/anti-HBS
2/anti-HBc
+) and 56
were vaccinated (HBSAg
2/anti-HBc
2/anti-HBS
+). All HBV in-
fected individuals were positive for anti-HBc. No acute HBV
infection was detected, as there were no individuals with anti-HBc
IgM.Viremiawasestimatedbyreal-timePCR(COBASHTaqManH
HBV assay) of all samples to confirm serological results. We also
evaluated HBV-infected individuals for HBeAg and anti-HBe.
After serology for HBV infection, 636 individuals remained in
the study. Plasma measurements of aspartate amino-transferase
(AST), alanine amino-transaminase (ALT), total bilirubin, hemo-
globin, fibrinogen and C-reactive protein (CRP) were made at the
clinical laboratory of Faculdade Sa ˜o Lucas and at the Pharmacy
School of the Federal University of Bahia, Brazil. A flow chart of
the study is shown in the Figure 1. The baseline characteristics of
the individuals are listed in the Table 1.
Plasma cytokine measurement
IL-10, IFN-c and TNF-a plasma levels were measured using the
Cytometric Bead Array - CBAH (BD Biosciences Pharmingen, San
Diego, CA, USA) according to the manufacturer’s protocol, with
all samples run in a single assay. The flow cytometric assay was
performed and analyzed by a single operator, and standard curves
were derived from cytokine standards.
Statistical analysis
In the exploratory analysis of the data, frequency tables were
constructed and the Chi-square test was applied to evaluate the
association between qualitative variables. One polynomic (multino-
mial) logistic regression model was carried out because the response
variable (current malaria infection) was classified into three groups
(non-infected, asymptomatic infection and symptomatic). The
following independent variables were included: HBV infection,
Figure 2. Adjusted multinomial logistic regression analysis of risk factors for asymptomatic malaria infection or for no malaria
infection compared to symptomatic malaria. Symptomatic malaria infection was considered the primary outcome. Adjustment was performed
for all variables presented. CI: Confidence interval. Individuals presenting AgHBS
2/anti-HBS
+/anti-HBc
+ with no HBV DNA amplification by
quantitative RT-PCR (qPCR) were considered to have previous HBV infection, those presenting AgHBS
+/anti-HBS
2 and detectable viremia by qPCR
were considered currently infected with HBV and those with AgHBS
2/anti-HBS
+/anti-HBc
2 were considered vaccinated against the virus. The
statistical significance was estimated through multinomial logistic regression.
doi:10.1371/journal.pone.0019841.g002
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age, gender and plasma cytokine levels of IL-10 or IFN-c. The
thresholdvaluesofIL-10orIFN-cplasma levels,whichdiscriminate
asymptomatic from symptomatic malaria infection with a high
likelihood ratio, were estimated using a ROC curve analysis to
categorize the individuals according to cytokine levels and to
perform the multinomial logistic regression (data not shown).
Malaria parasitemia, cytokine plasma levels, and plasma levels of
AST, ALT, total bilirubin, fibrinogen, and CRP were compared
between groups using the Kruskal-Wallis test with Dunn’s multiple
comparisons. HBV DNA plasma levels were compared between
groups using the Mann-Whitney test. The correlation between
Plasmodium parasitemia and HBV viremia in co-infected individuals
was checked using the Spearman test. We also plotted a non-linear
curve fit to illustrate the general trend of this correlation. For each
analysis, P,0.05 was considered statistically significant. The
statistical analysis was performed using the software STATA 9.0
(StataCorp, TX, USA). The graphics were plotted using GraphPad
Prism 5.0 (GraphPad Software Inc., USA).
Results
Baseline characteristics
A total of 636 individuals, out of 681 initially approached, were
included. Individuals presenting no malaria infection differed from
those presenting asymptomatic or symptomatic Plasmodium infec-
Table 2. Baseline characteristics of the subjects, considering only Plasmodium vivax infections.
Current vivax malaria
Variables
Non-infected
n=205
Symptomatic infection
n=190
Asymptomatic infection
n=173
P value
x2
n( % ) n( % ) n( % )
Gender 0.0741
Male 88 (42.93) 102 (53.68) 77 (44.51)
Age (years) ,0.0001
5 to 15 14 (6.83) 24 (12.63) 1 (0.58)
16 to 30 50 (24.39) 63 (33.16) 25 (14.45)
31 to 59 98 (47.80) 77 (40.53) 120 (69.36)
$60 21 (10.24) 18 (9.47) 17 (9.83)
Years residing in the area ,0.0001
#2 44 (21.46) 51 (26.84) 27 (15.61)
3 to 10 20 (9.76) 38 (20.0) 17 (9.83)
.10 119 (58.05) 93 (48.95) 119 (68.79)
Residents per household ,0.0001
1 to 5 141 (68.78) 107 (56.32) 118 (68.21)
.5 42 (20.49) 75 (39.47) 45 (26.01)
HBV infection ,0.0001
Non-infected 89 (43.41) 132 (69.47) 74 (45.40)
Previous HBV 65 (31.70) 47 (24.74) 64 (39.26)
Current HBV 29 (14.15) 03 (1.58) 25 (15.34)
Vaccinated 22 (10.73) 08 (4.21) 10 (5.78)
Malaria episodes ,0.0001
None 24 (11.71) 25 (13.16) 03 (1.73)
1 to 4 07 (3.41) 52 (27.37) 02 (1.16)
5 to 10 29 (14.15) 45 (23.68) 04 (2.31)
.10 123 (60.0) 60 (31.58) 154 (89.01)
Serum IL-10 (pg/mL) 1 ,0.0001
#46 175 (85.37) 139 (73.16) 42 (24.28)
.46 08 (3.90) 43 (22.63) 121 (69.94)
Serum IFN-c (pg/mL) 1 ,0.0001
#198 154 (75.12) 111 (58.42) 118 (68.21)
.198 29 (14.15) 71 (37.37) 45 (26.01)
A Chi-square test was performed to compare the distribution of each variable between the groups.
Individuals presenting AgHBS
2/anti-HBS
+/anti-HBc
+ with no HBV DNA amplification by quantitative RT-PCR (qPCR) were considered to have previous HBV infection,
those presenting AgHBS
+/anti-HBS
2 and detectable viremia by qPCR were considered currently infected with HBV and those with AgHBS
2/anti-HBS
+/anti-HBc
2 were
considered vaccinated against the virus.
1Cut-off IL-10 and IFN- c plasma levels were determined by choosing the values that which implied the highest likelihood ratio in discriminating asymptomatic from
symptomatic malaria infection using a ROC analysis.
doi:10.1371/journal.pone.0019841.t002
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(Table 1). A total of 254 individuals presented serological markers
of natural exposure to HBV, and 61 were experiencing infection at
the time of the study (as identified by HBSAg and detectable viral
load) (Table 1).
Individuals not included in the study (N=45) were similar to
those enrolled with regard to age, time of residence in the endemic
area, number of residents per household, and number of previous
malaria episodes, but were more likely to be female (P=0.03) and
test negative for Plasmodium sp. infection on thick smear
examination (P=0.001) and for markers of HBV exposure
(P=0.02). As expected, gender did not show any association with
the absence of malaria or with asymptomatic infection (Figure 2).
Impact of HBV exposure on malaria clinical presentation
To identify the variables independently associated with
asymptomatic malaria, we performed a multinomial logistic model
with adjustment for the all variables studied. We included
variables previously described as protective factors against malaria
[11,15,16], such as age, time of residence in the endemic area and
number of previous malaria episodes. According to this analysis,
age and increased number of previous malaria episodes were
independently associated with asymptomatic infection (Figure 2).
A high number of residents per household was associated with the
occurrence of symptomatic malaria (odds ratio: 0.38, 95% CI:
0.19 to 0.74, P,0.0001; Figure 2). Vaccination against HBV did
not influence the clinical presentation of malaria (OR: 1.05, 95%
CI: 0.5 to 2.21; Figure 2). Previous HBV infection was associated
with asymptomatic infection (OR: 2.43, 95% CI: 1.06-5.61,
P,0.0001; Figure 2), and current HBV infection was even more
robustly related to asymptomatic malaria (OR: 120.13, 95% CI:
19.75-730.64, P,0.0001; Figure 2).
We also tested whether the cytokine balance is associated with
clinical immunity to malaria by examining the levels of two
cytokines that indicate an inflammatory profile [11,15,16]. We
found that increased plasma levels of IL-10 (values above 46 pg/
mL) were independently associated with asymptomatic malaria
(OR: 16.56, 95% CI: 7.59–36.16, P,0.0001), whereas higher
levels of IFN-c (values above 198 pg/mL) were related to the
occurrence of symptomatic infection (OR: 0.13, 95% CI: 0.05–
0.21, P,0.0001; Figure 2).
We then re-analyzed the data considering only the P. vivax cases,
which represented 84.22% of the cases in our study (Table 2). The
distribution of the epidemiologic, demographic and immunologic
variables using only vivax malaria cases was similar to the previous
analysis of both P. vivax and P. falciparum infections (Table 2). The
exclusion of the P. falciparum cases did not alter the associations
between HBV infections or the cytokine plasma levels with the
occurrence of asymptomatic Plasmodium infection (Figure 2, left
panel). Thus, the patterns of epidemiological associations did not
change between the P. vivax and P. falciparum malaria cases. In
addition, the systemic levels of both inflammatory patterns and
cytokines did not significantly change between the infections from
P. vivax and/or P. falciparum (data not shown), which allowed us to
continue to analyze P. vivax and P. falciparum cases together.
HBV exposure and laboratory assessment of malaria
severity
To investigate the possible effects of active or previous HBV
infection on the malaria severity, we compared malaria parasitemia
between symptomatic or asymptomatic malaria cases, stratifying
according to HBV status. Notably, in both symptomatic and
asymptomatic individuals, active or previous HBV infection was
linked to lower Plasmodium parasitemia (Figure 3A). Conversely, the
number of HBV DNA copies/mL of blood in individuals infected
withHBValonewashigherthan inthoseco-infected with HBVand
Plasmodium (P,0.0001; Figure 3B). In addition, these groups did not
present significant differences in HBe antigen positivity (P=0.063;
Figure 3. Individuals co-infected with Plasmodium sp. and HBV
present lower parasitemia and higher viremia. (A) Individuals
presenting with symptomatic or asymptomatic malaria were stratified
according to the HBV status, and parasitemia levels were determined by
light microscopy as described in the methods. The number of
participants in each group is described in Table 1. Values were
compared by the Kruskal-Wallis test with Dunn’s multiple comparisons
posttest. (B) HBV viremia was estimated by real-time PCR in both HBV
infected (n=29) or HBV-malaria co-infected (n=32) individuals using
the Mann-Whitney test and the percentage of HBeAg positive cases was
also compared to these groups (C) using Fisher’s exact test. Lines and
boxes represent medians and interquartile ranges, and whiskers
represent minimum and maximum values. (D) Spearman correlation
between Plasmodium parasitemia and HBV viremia in co-infected
individuals (n=32). A non-linear curve fit was used to illustrate the
general trend of the correlation. *P,0.05; ***P,0.0001.
doi:10.1371/journal.pone.0019841.g003
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HBV-malaria co-infection. Remarkably, in co-infected individuals,
there was a significant negative correlation between Plasmodium
parasitemia and HBV viremia (Spearman r=20.6; P=0.0003)
(Figure 3D).
The clinical presentation of both malaria and hepatitis B are
correlated with cytokine balance. In the present study, individuals
co-infected with HBV and Plasmodium presented similar systemic
levels of IFN-c compared with those infected solely with HBV
(Figure 4). Nevertheless, co-infected individuals presented signif-
icantly higher plasma concentrations of IL-10 and slightly reduced
levels of TNF-a compared with HBV mono-infected patients
(Figure 4). Notably, HBV malaria co-infection was associated with
reduced values of IFN-c/IL-10 ratios (P,0.0001, compared with
HBV mono-infection; Figure 4). Patients with symptomatic
malaria presented with higher levels of AST, ALT, total bilirubin
and CRP compared to both asymptomatic malaria and non-
infected individuals (Figure 5A–D). In this scenario, previous or
current HBV infection did not change the levels of these
parameters, in addition to not modifying the overall prevalence
of symptoms (Figure 5E).
Discussion
This study is the first to provide strong evidence for the
association between HBV and reduced malaria severity. Plasmo-
dium-infected individuals with active or previous HBV infection
were significantly more likely to be asymptomatic, to present with
lower parasitemia and to have a decreased inflammatory cytokine
profile. Co-infected individuals presented higher HBV viremia,
and Plasmodium parasitemia was correlated to plasma HBV DNA
titers. Additionally, the cytokine balance seems to be linked to
disease severity, as individuals with asymptomatic malaria
presented a reduced IFN- c/IL-10 ratio. However, other factors
in addition to cytokine profile must be involved in the reduced
malaria severity in individuals with HBV, as the risk for
asymptomatic infection was even higher when we analyzed the
adjustment for plasma IL-10 and IFN-c levels. It is possible that
modifications in the hepatic microenvironment during HBV
infection reduce the organ’s susceptibility to Plasmodium.
This study confirms previous observations that asymptomatic
Plasmodium infection correlates with increased age and longer
periods of residency in regions where malaria is endemic [17,18].
In addition, elevated IL-10 plasma levels correlated significantly
with asymptomatic Plasmodium infection. Perhaps continued
exposure to Plasmodium leads to IL-10 mediated immunomodula-
tory effects that limit immunopathology. IL-10 responses have
been linked to human resistance to malaria [19]. HBV infection
leads to increased IFN-c levels [20,21]. It has been shown that
IFN-c is important for Plasmodium clearance in the liver [22], in
addition to its early importance for malaria clinical immunity [23].
In co-infected individuals, higher IFN-c production could decrease
parasitemia, leading to reduced malaria severity. However,
Plasmodium infection is related to increased IL-10 plasma levels
[24,25]. Higher IL-10 production is related to reduced tissue
damage in several diseases, including experimental [26] and
human malaria [27,28]. Polymorphisms associated with increased
IL-10 production are related to increased severity of chronic HBV
infection [29,30]. In the present study, individuals presenting
asymptomatic malaria displayed a lower IFN- c/IL-10 ratio than
their symptomatic counterparts. Thus, IL-10 may be linked to
reduced malarial liver damage as well as increased viral load.
Other studies have addressed the association between HBV
infection and P. falciparum but not P. vivax malaria. In one study, an
association between HBV carriage and malaria severity was
observed in children [31]. Another investigation suggested that
chronic asymptomatic P. falciparum infection may be accompanied
by sustained periods of HBV reactivation [4]. However, these data
are limited in that only four patients were studied. More recently,
one observational study in an Asian hospital proposed that chronic
HBV infection exacerbates P. falciparum malaria [5]. However, that
study analyzed only patients hospitalized with severe P. falciparum
Figure 4. Co-infection with Plasmodium and HBV alters plasma cytokine profile. Plasma levels of IFN-c, IL-10 and TNF-alpha were compared
between individuals currently infected with HBV (n=29) and those co-infected with HBV and malaria (n=32). Lines and boxes represent median and
interquartile range, and whiskers represent minimum and maximum values. Data were compared using a Mann-Whitney test. P values are shown in
each graph.
doi:10.1371/journal.pone.0019841.g004
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malaria. In addition, the overall risk of death was not significantly
higher in the co-infected patients [5]. Our study suggests that, in
general, HBV does not worsen the pro-inflammatory cytokine
parameters also altered by Plasmodium infection. In addition,
exposure to HBV did not influence the frequency of hospitaliza-
tion or even the prevalence of symptoms. The multivariate analysis
revealed that other factors in addition to HBV infection might
influence asymptomatic malaria. We propose that in older persons
repeatedly exposed to Plasmodium, HBV exposure reduces
parasitemia but does not alter organ dysfunction caused by
malaria. Thus, a common mechanism affecting malaria immunity
is postulated.
We recognize some limitations to this study. First, it is unclear
whether the plasma cytokines reflect cytokine levels in the liver.
Further studies are underway to address this issue. In addition, we
Figure 5. HBV infection did not alter either laboratory markers of organic dysfunction or the prevalence of symptoms in malaria
cases. The study participants were stratified according to the clinical presentation of Plasmodium infection and also according to the HBV natural
exposure and plasma levels of (A) alanine-aminotransferase (ALT), (B) total bilirubin, (C) C-reactive protein and (D) fibrinogen were compared using a
Kruskal-Wallis test with Dunn’s multiple comparisons. Lines and boxes represent medians and interquartile ranges, while whiskers represent
minimum and maximum values. (E) The prevalence of diverse malaria-related symptoms was measured in individuals presenting with symptomatic
malaria and compared between those with previous or current HBV infection and those with no markers of HBV exposure. The values were compared
using Chi-square test and no significant differences were found.
doi:10.1371/journal.pone.0019841.g005
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phosphate dehydrogenase deficiency (G6PD). Helminth infection
can affect malaria [32] by reducing the associated immunopa-
thology [33,34]. Recently, it was demonstrated that filarial
infection modulates malaria-specific type-1 cytokine responses in
an IL-10 dependent manner [35]. Our facilities were not prepared
to perform fecal exams in all individuals. Local publications
indicate that the prevalence of G6PD in Rondo ˆnia is about 3.3%
[36], which would not interfere with our conclusions.
In conclusion, HBV infection seems to modify the physiology of
the host’s immune system, stimulating increased inflammatory
responses, reducing Plasmodium parasitemia and possibly diminish-
ing parasite burden. The results presented here need to be
confirmed in future prospective studies.
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